AZ will present new data on Merck & Co/MSD-partnered ... BRCA-positive breast cancer. GSK has high hopes for Zejula – currently only approved for second-line ovarian cancer treatment – and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback